A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients

Jeon et al., NCT04713176, NCT04713176, Dec 2022
240 patient camostat late treatment RCT with results not reported over 3 years after completion.
5 camostat RCTs have results missing long after expected1-5
The trials report a total of 828 patients, with 4 trials having actual enrollment of 578, and the other estimated.
Jeon et al., 9 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, South Korea, trial NCT04713176 (history). Contact: mdjjh@nmc.or.kr.
Late treatment
is less effective